PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders

FHS
May 22, 2024
5:58 am

PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced the introduction of GlueSEEKER™.

Urologist weighs in on why men avoid doctor visits

Data has consistently shown that men are reluctant to seek medical care despite the fact they generally face higher mortality rates and shorter life expectancies

August 6, 2024

The pharmaceutical industry keeps losing Washington friends

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in

July 9, 2024

AstraZeneca bails on roxadustat’s future in the US, but keeps China pact with FibroGen

AstraZeneca is handing back US and certain other regional rights for roxadustat to FibroGen, ending a two-and-a-half-year limbo that followed an FDA rejection of the

February 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.